Markets:

Overview

News

Currencies

International

Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

5.810 +0.170 (+3.01%)

Streaming Delayed Price Updated: 1:36 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection ↗

November 10, 2025

Via Stocktwits

Tesla Chair Declares Start Of 'Whole New Book' As Musk's 423 Million Share Award Is Locked In — All Hope Pinned On Robotaxi, Optimus ↗

November 10, 2025

Via Stocktwits

Top Stocks With Earnings This Week: Plug, Oklo, Circle And More ↗

November 10, 2025

Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.

Via Benzinga

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Preview: Capricor Therapeutics's Earnings ↗

November 07, 2025

Via Benzinga

Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder ↗

September 25, 2025

Via Stocktwits

Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback ↗

November 04, 2025

Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency.

Via Stocktwits

Why Capricor Therapeutics Stock Is Surging Today ↗

September 25, 2025

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics.

Via Benzinga

Gapping stocks in Thursday's session ↗

September 25, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Via Chartmill

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week ↗

September 03, 2025

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.

Via Benzinga

Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting ↗

August 22, 2025

Biohaven shares rise as FDA removes advisory committee meeting for troriluzole in spinocerebellar ataxia, with decision expected in late 2025.

Via Benzinga

C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

August 11, 2025

Via Benzinga

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket ↗

August 11, 2025

Via Benzinga

REPL Stock Nearly Doubled In Value Today: What's Going On? ↗

July 30, 2025

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 30, 2025

Via Benzinga

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

These stocks are moving in today's pre-market session ↗

July 30, 2025

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 30, 2025

Via Benzinga

Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket ↗

July 30, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

July 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 11, 2025

Via Benzinga

Which stocks are moving on Friday? ↗

July 11, 2025

Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Capricor Therapeutics Hammered On A Surprise FDA Rejection ↗

July 11, 2025

The company is currently running another study with results due in the third quarter.

Via Investor's Business Daily

There are notable gap-ups and gap-downs in today's session. ↗

July 11, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock ↗

July 11, 2025

FDA rejected Capricor's BLA for Deramiocel due to insufficient evidence, requesting more clinical data to support approval for Duchenne therapy.

Via Benzinga

Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy ↗

July 11, 2025

The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and...

Via Stocktwits

Wondering what's happening in today's pre-market session? ↗

July 11, 2025

The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 11, 2025

Via Benzinga

Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket ↗

July 11, 2025

Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers and losers noted.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.